A systematic review and meta‐analysis of the efficacy and safety of tirzepatide in patients with T2D found that tirzepatide decreased HbA1c by 0.36% and fasting serum glucose by 13.00 mg/dL when compared with GLP‐1 RAs (semaglutide 1 mg and others).61 Here, GLP1R is linked to type 2 diabetes mellitus.